Moleculin Biotech Inc. Daily Stock Analysis

Daily Stock Analysis, MBRX, Moleculin Biotech Inc, priceseries

Moleculin Biotech Inc. Daily Stock Analysis
Stock Information
Open
1.32
Close
1.27
High
1.36
Low
1.25
Previous Close
1.32
Daily Price Gain
-0.05
YTD High
1.95
YTD High Date
Jan 3, 2022
YTD Low
1.25
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.63
YTD Gain
-33.16%
52 Week High
4.77
52 Week High Date
Mar 30, 2021
52 Week Low
1.25
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-2.60
52 Week Gain
-67.18%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 16. 2017
4.86
Jun 30. 2017
11.41
10 Trading Days
134.76%
Link
LONG
Jul 17. 2017
10.20
Aug 8. 2017
15.52
16 Trading Days
52.16%
Link
LONG
Feb 13. 2018
10.62
Feb 20. 2018
11.91
4 Trading Days
12.15%
Link
LONG
Jun 5. 2018
10.68
Jun 21. 2018
11.40
12 Trading Days
6.74%
Link
LONG
Nov 23. 2018
8.22
Nov 28. 2018
8.67
3 Trading Days
5.47%
Link
LONG
Jan 2. 2019
6.72
Jan 22. 2019
8.18
13 Trading Days
21.71%
Link
LONG
Apr 18. 2019
6.66
Apr 25. 2019
8.88
4 Trading Days
33.38%
Link
LONG
Apr 13. 2020
7.14
Apr 17. 2020
7.56
4 Trading Days
5.88%
Link
LONG
Jan 4. 2021
5.10
Jan 20. 2021
5.77
11 Trading Days
13.19%
Link
Company Information
Stock Symbol
MBRX
Exchange
NasdaqCM
Company URL
http://www.moleculin.com
Company Phone
713-300-5160
CEO
Walter V. Klemp
Headquarters
Texas
Business Address
2575 WEST BELLFORT, SUITE 333, HOUSTON, TX 77054
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001659617
About

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company, which focuses on the development of anti-cancer drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms; and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Description

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading